Medicine and Dentistry
ABC Transporter Subfamily B
27%
Acute Leukemia
19%
Acute Myeloid Leukemia
18%
Alisertib
14%
Antigen Expression
17%
Arm
15%
B Cell
37%
B-Cell Chronic Lymphocytic Leukemia
25%
B-Cell Lymphoma
12%
Cancer
24%
CHOP
36%
Clinical Feature
12%
Cyclophosphamide
19%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Diffuse Large B-Cell Lymphoma
27%
Disease
46%
Doxorubicin
14%
Follicular Lymphoma
23%
Gene Expression
11%
Immunophenotyping
24%
Immunosurveillance
12%
Involved-Field Radiotherapy
19%
Large-Cell Lymphoma
36%
Leukemia
19%
Liposomal Daunorubicin
19%
Lymphocytic Lymphoma
34%
Lymphoma
34%
Lymphoproliferative Disease
21%
Major Histocompatibility Complex
19%
Mantle Zone
14%
Monoclonal Antibody Ki 67
19%
Multidrug Resistance
19%
Multiple Myeloma
19%
Myeloma
17%
Neoplasm
47%
Nerve Cell Adhesion Molecule
19%
Non-Hodgkin Lymphoma
55%
Oncology
51%
Overall Survival
32%
Peripheral T-Cell Lymphoma
42%
Plasma Cell
16%
Prednisone
19%
Prognostic Factor
20%
Progression Free Survival
32%
Radioimmunotherapy
23%
Rituximab
40%
T Cell
30%
T Lymphocyte
19%
Tositumomab
31%
Vincristine Sulfate
15%
Immunology and Microbiology
Acquired Immune Deficiency Syndrome
9%
Antigen Expression
11%
Arm
11%
B Cell
100%
Bcl-2
8%
Blood Plasma
9%
CD56 Antigen
9%
Cell Adhesion Molecule
10%
Cell Line
21%
Cyclophosphamide
15%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Cytotoxicity
9%
Gene Expression
9%
Gene Rearrangement
9%
Genetic Polymorphism
9%
Granuloma
9%
HLA-DR
24%
Human Immunodeficiency Virus
9%
Humoral Immunity
9%
Ibritumomab Tiuxetan
9%
Immunocompetence
9%
Immunosurveillance
12%
Intravenous Immunoglobulin
9%
Lactate Dehydrogenase Blood Level
11%
Lymphoma Cell
73%
Major Histocompatibility Complex
19%
Monoclonal Antibody Ki 67
9%
Monospecific Antibody
11%
Multidrug Resistance
12%
Multiple Myeloma
32%
Myeloma Cell Line
10%
Neural Cell Adhesion Molecule
9%
Overall Survival
29%
Oxidative Stress
9%
P-Glycoprotein
21%
Peripheral T-Cell Lymphoma Not Otherwise Specified
9%
Plasma Cell
12%
Prednisone
15%
Prevalence
9%
Progression Free Survival
32%
Protein Expression
9%
Receptor Binding
9%
Rituximab
25%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Sezary Cell
9%
Single Nucleotide Polymorphism
9%
T Cell
60%
T Lymphocyte Antigen
9%
Tositumomab
21%
Tumor Cell
11%
Keyphrases
Aberrancy
12%
Aggressive non-Hodgkin Lymphoma
11%
Alisertib
24%
Aurora
10%
Aurora A
9%
Aurora B
9%
B Cells
16%
Chemotherapy
24%
Chronic Lymphocytic Leukemia
12%
COVID-19
9%
Cyclophosphamide
11%
Diffuse Large B-cell Lymphoma (DLBCL)
48%
Dioleoylphosphatidylethanolamine
9%
Drug Resistance
11%
EVI1
9%
Follicular Lymphoma
18%
HLA-DR
25%
Immune Parameters
15%
Immunoglobulin
11%
Immunophenotyping
19%
Induced Apoptosis
11%
Involved Field Radiotherapy
12%
Iodine-131 (131I)
19%
Ki-67
19%
Lymphoma
31%
Lymphoma Cells
12%
Lymphoma Patients
15%
Lymphoproliferative Disorders
12%
Mantle Zone
13%
MHC Class II
9%
Monoclonal Antibody
20%
Multidrug-resistant
12%
Non-Hodgkin Lymphoma
17%
Outcome Prediction
19%
Overall Survival
13%
P-glycoprotein (P-gp)
19%
P-glycoprotein Expression
11%
Peripheral T-cell Lymphoma
19%
Phase II Study
15%
Plasma Cell Myeloma
19%
Prednisone
9%
Prognostic Factors
11%
Prognostic Significance
22%
Progression-free Survival
19%
Radioimmunotherapy
17%
Rituximab
25%
Small Lymphocytic Lymphoma
14%
Solid Tumors
9%
Southwest Oncology Group
19%
Tositumomab
29%
